MNPR at a glance
Monopar Therapeutics (MNPR, SEC CIK 1645469) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Monopar Therapeutics (MNPR) reported revenue of $0 and a net loss of $13.7 million. Diluted EPS was -$1.85.
- As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Monopar Therapeutics (MNPR) shares worth $101.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Tsuchimoto Kim R on November 4, 2026 of 1,295 shares at $70.75 per share.
- In the last 90 days, MNPR insiders reported 0 open-market purchases ($0) and 34 open-market sales ($5.3M) on Form 4, a net sale of $5.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 34 sells
- Net −$5.3M
- 13F holders
- 20 funds
- $101.7M · −2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New regulatory risk: rolling ALXN1840 NDA submission and review, with potential U.S. government shutdown delays
- Most material program change: Alexion terminated ALXN1840 Wilson disease development after Phase 2 review and regulator discussions
- Operational risk: radiopharmaceutical programs depend on adequate radioisotope supply and time-limited product shelf life
- Market risk: larger competitors possess greater capital, organizational, marketing and sales resources
- Financial risk: $104.9 million accumulated deficit, with operations funded through March 31, 2028 by current cash and investments
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved drugs or product sales
- Net loss $6.2M vs $3.4M YoY, operating loss $7.5M vs $4.1M
- R&D expense $4.4M vs $2.6M YoY, G&A expense $3.0M vs $1.5M
- Cash, equivalents and investments $129.4M as of September 30, 2026
- Operating cash outflow $12.9M vs $9.1M YoY, funds expected through March 31, 2028; NDA rolling submission completion anticipated within several weeks
AI summary of the MNPR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release furnished as Exhibit 99.1, containing the company’s reported results and management commentary
Item EX-99.1: Item EX-99.1
- Q3 2026 net loss widened to $6.2M, or $0.72 per share, from $3.4M, or $0.48 per share
- Cash, equivalents and investments totaled $129.4M, supporting operations through at least March 31, 2028
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss widened to $5.3M, or $0.62 per share, from $2.5M, or $0.35 per share
- Cash, equivalents and investments totaled $134.3M, supporting operations through at least December 31, 2027
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026 announced by Monopar Therapeutics
- Full financial details and management commentary contained in Exhibit 99.1 press release
Item 7.01: Regulation FD Disclosure
- Rolling FDA NDA submission initiated for ALXN1840 (tiomolibdate choline) in Wilson disease
- Regulatory milestone potentially accelerates FDA review of Monopar’s lead therapeutic candidate
Item EX-99.1: Item EX-99.1
- Rolling NDA submission initiated for ALXN1840, advancing Monopar’s lead program toward potential U.S. approval in Wilson disease
- FDA filing authorization enables completed sections to undergo review before the application is complete
AI summaries of MNPR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MNPR
Don't miss the next MNPR filing
- Alerts as it files. A push when MNPR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MNPR, by share count.
- Ask anything. An AI agent that reads every MNPR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Tsuchimoto Kim R | M | Nov 4, 2026 | 856 | - |
| Tsuchimoto Kim R | M | Nov 4, 2026 | 2,035 | $14.00 |
| Tsuchimoto Kim R | Sell | Nov 4, 2026 | 1,295 | $70.75 |
| Tsuchimoto Kim R | Sell | Nov 4, 2026 | 600 | $72.21 |
| Tsuchimoto Kim R | M | Nov 4, 2026 | 2,035 | - |
| Tsuchimoto Kim R | Sell | Nov 4, 2026 | 996 | $71.35 |
| Tsuchimoto Kim R | M | Nov 4, 2026 | 856 | $30.00 |
| Anderson Raymond | M | Nov 2, 2026 | 1,740 | $30.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $0 | $0 | $0 |
| Operating Income | -$8.8M | -$16.2M | -$16.7M |
| Net Income | - | -$15.6M | -$13.7M |
| Balance Sheet | |||
| Total Assets | $7.3M | $60.3M | $140.7M |
| Equity | $5.6M | $55.0M | $137.8M |
| ROE | - | -28.3% | -10.0% |
| Per Share | |||
| EPS | $-0.61 | $-4.11 | $-1.85 |
| Cash Flow | |||
| Operating CF | -$7.9M | -$6.4M | -$12.2M |
Source: XBRL data in Monopar Therapeutics (MNPR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MNPR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 20 | $101.7M |
| Q2 2026 | 22 | $91.4M |
| Q1 2026 | 19 | $59.0M |
| Q4 2025 | 18 | $59.9M |
| Q3 2025 | 13 | $46.2M |
| Q2 2025 | 14 | $14.7M |
| Q1 2025 | 9 | $5.9M |
| Q4 2024 | 2 | $1.2M |
- State Street Corp+137.2K (+148%)
- Goldman Sachs Group+71.7K (+444%)
- Ameriprise Financial+33.0K (+186%)
- Morgan Stanley+20.1K (+112%)
- Citadel Advisors LLC+10.9K (+29%)
- Vanguard Portfolio Management LLC−6.0K (-12%)
- Wells Fargo & Co−2.9K (-72%)
- BNY Mellon−2.1K (-3%)
- Millennium Management−1.7K (-3%)
- D.E. Shaw & Co+14.7K
- Raymond James Financial−5.5K
- Invesco Ltd−2.4K
- FMR LLC (Fidelity)−530
Source: 13F-HR filings on SEC EDGAR (aggregated from 117 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MNPR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MNPR SEC filings: frequently asked questions
Are MNPR insiders buying or selling?
In the last 90 days, Monopar Therapeutics (MNPR) officers, directors and 10% owners reported no open-market purchases and 34 open-market sales worth $5.3 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MNPR stock?
As of September 30, 2026, the largest Monopar Therapeutics (MNPR) holders among the 13F filers tracked by SignalX were BlackRock ($27.8 million), State Street Corp ($18.3 million), Vanguard Capital Management LLC ($17.4 million), Goldman Sachs Group ($7.0 million), BNY Mellon ($6.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MNPR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Monopar Therapeutics (MNPR) reported revenue of $0 and a net loss of $13.7 million. Diluted EPS was -$1.85. The figures come from the XBRL data in the 10-K.
What did MNPR report in its latest 8-K?
Monopar Therapeutics (MNPR) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest MNPR SEC filings?
Monopar Therapeutics (MNPR) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 4, 2026.
What is MNPR's SEC CIK number?
Monopar Therapeutics (MNPR)'s SEC Central Index Key (CIK) is 1645469. EDGAR lists every MNPR filing under that number.
Ask anything about MNPR
The research agent reads MNPR's filings, financials, insider trades and 13F holders, then answers with sources.